![Janet L. Smart](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Janet L. Smart
Keine laufenden Positionen mehr
Profil
Janet L.
Smart worked as a Senior Director-Legal Affairs at Anchor Therapeutics, Inc. from 2010 to 2011.
She also worked as Secretary & Vice President-Intellectual Property at Proteostasis Therapeutics, Inc. Dr. Smart received her undergraduate, graduate, and doctorate degrees from Northeastern University.
She also received a graduate degree from the University of New Hampshire School of Law.
Ehemalige bekannte Positionen von Janet L. Smart
Unternehmen | Position | Ende |
---|---|---|
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | General Counsel | 01.10.2011 |
PROTEOSTASIS THERAPEUTICS, INC. | General Counsel | - |
Ausbildung von Janet L. Smart
University of New Hampshire School of Law | Graduate Degree |
Northeastern University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Proteostasis Therapeutics, Inc.
![]() Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |